Evolution of First-Line Immune Checkpoint Inhibition in Advanced or Metastatic Solid Tumors - Episode 2

A Historical Perspective on First-Line Treatment of NSCLC and Recent Advances in Immunotherapy

In the first installment of this series, Joshua Sabari, MD, provides an overview on the use of chemotherapy for first-line treatment of NSCLC, and discusses how the more recent availability of PD-1/PD-L1– and CTLA-4–targeted immunotherapy is changing the field.